Share this article
Share this article
RIDGEFIELD, Conn., April 23, 2021 /PRNewswire/ Boehringer Ingelheim today announced results from a phase III, randomized study that concluded that switching several times from Humira® (adalimumab) to Cyltezo® (adalimumab-adbm) produced similar clinical outcomes in terms of pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate-to-severe chronic plaque psoriasis. The 32-week data will be presented at the American Academy of Dermatology 2021 virtual meeting experience. We are proud to present the results from Voltaire-X, a landmark study that supports Boehringer Ingelheim s application for interchangeability between Cyltezo® and Humira®, said Thomas Seck, Senior Vice President, Medicine and Regulatory Affairs at Boehringer Ingelheim. This first-of-its-kind switching study further reinforces our goal to broaden access to biosimilar treatment options while contributing to the quality and sustainability of healt
Virology Market 2021 proliferating Extensive Business Opportunities Till 2027 | Top Market Leaders as Abbott, Johnson and Johnson Services Inc , F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc & More
sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Virology Market 2021 proliferating Extensive Business Opportunities Till 2027 | Top Market Leaders as Abbott, Johnson and Johnson Services Inc , F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc & More
texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
Jardiance® associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Share Article
Highmark and Boehringer Ingelheim announced positive results from their outcomes-based agreement, which showed that adults with type 2 diabetes and known cardiovascular disease who took Jardiance® (empagliflozin) had a lower annual total cost of care compared with those prescribed other branded or generic anti-hyperglycemic medications. Patients on Jardiance demonstrated a reduction in medical costs of over 30%. Factoring in both medical and pharmacy costs, the overall total cost of care reduction was more than 20% for patients on Jardiance.